Cardiovascular diseases are the major causes of illness and death in women. Premenopausal women are relatively protected from coronary artery disease and atherosclerosis as compared to postmenopausal women, and this protection is attributed to the effects of the female sex hormone (estrogen). The vasculature, like the reproductive tissues, bone, liver, and brain, is now recognized as an important site of estrogen's action. Although estrogen's beneficial effects on the cardiovascular system are well described in many studies, the molecular basis of estrogen protective mechanisms are still quite vague. Both genomic mechanisms, mediated primarily through estrogen receptor alpha (ERa) and estrogen receptor beta (ERb), and non-genomic mechanisms, through nitric oxide (NO), of estrogen action are controversial and do not entirely explain the effects of estrogen on vascular preservation during conditions of oxidative stress. Until recently, the atheroprotective effects of estrogen were attributed principally to its effects on serum lipid concentrations and cholesterol levels. However, two recent reports that estrogen therapy has no effect on the progression of coronary atherosclerosis in women with established disease, despite the favorable changes in LDL and cholesterol levels, leads to questions about the lipid / cholesterol mechanism of estrogen-mediated effects on atherosclerosis. Alternatively, the high level of homocysteine, found to correlate with accelerated cardiovascular disease and identified as an independent risk factor for atherosclerosis, was recently described to be diminished by estrogen. Protection against disturbed sulfhydryl metabolism and higher homocysteine level could be the missing link in understanding how exactly estrogen affects vascular cells metabolism and responses to oxidative stress. This review focuses on estrogen / homocysteine interactions and their relevance to the cardiovascular system.
Introduction
early epidemiological study showed that estrogen replacement therapy (ERT) in postmenopausal women leads to Women in Western societies generally live close to one significant reduction of the risk of myocardial infarction half of their lives after the onset of menopause, during [3] . Since then, ERT has been prescribed for treating which they are at progressively increased risk for developperimenopausal symptoms and future prevention of posting cardiovascular disease. While the death rate from menopausal cardiovascular disease. coronary artery disease (CAD) is five to eight times greater This clinical practice was mainly based on widely in men than in women during ages 25-55 years [1] , this accepted theory that the preventive effects of estrogen difference in mortality rate narrows considerably after against atherosclerosis are mediated through its effects on menopause and suggests that premenopausal women have cholesterol and lipid metabolism. However, estrogen mevascular / endothelial protective factors lost after menodiated protection against atherosclerosis in LDL receptorpause. More than 40 years ago, Pick et al. [2] observed that deficient mice was found to be independent of estrogen's estradiol benzoate reduced the incidence of atherosclerotic effect on plasma cholesterol / lipid levels [4] . Furthermore, lesions in coronary arteries of cholesterol-fed chicks. An recent randomized studies (HERS) in women with established coronary artery disease demonstrated no benefit of estrogen replacement therapy, in spite of its favorable effects on lipid profile and cholesterol level [5, 6] . At the glutathione pool in human liver cells is derived from same time, many investigations confirm that estrogens homocysteine via the transsulfuration pathway [31] . The have remarkable beneficial effects on endothelial integrity, redox sensitivity of the transsulfuration pathway can be inhibit smooth muscle cell proliferation and migration and rationalized as an auto-corrective response that leads to an activate the anti-oxidant system, etc. [7] [8] [9] [10] [11] [12] . This disincreased level of glutathione synthesis in cells challenged crepancy in the reports from basic science research and by oxidative stress. The importance of the homocysteinerandomized clinical trials indicates that other mechanisms dependent transsulfuration pathway is the maintenance of must have outweighed the beneficial effects of estrogens the intracellular glutathione pool, and the regulation of this on vasculature, beyond their effects on plasma lipids.
pathway under oxidative stress conditions. Aberrations in Alternatively, McCully has established the homocysteine this pathway could compromise the redox buffering theory of atherosclerosis in the 1970s and since then many capacity of cells, which may in turn may be related to the reports confirm that homocysteine metabolism is an impathophysiology of the different homocysteine-related portant mediator in development of atherosclerosis and diseases. Whether homocysteine by itself is involved in the cardiovascular disease. In previous studies, in vitro and in pathogenesis of these multi-organ system disorders is the vivo, we observed that estrogen prevents vascular injury in topic of current investigations. conditions of experimentally induced hyperhomocysteinemia and decreases homocysteine level in 2.1. Homocysteine a basis for atherosclerosis? both controls and animals on hyperhomocysteinemic diet [13, 14] . Higher concentrations of homocysteine are a Atherothrombotic vascular events were linked to raised source of hydrogen peroxide, a harmful free radical, which total homocysteine levels in patients with homocysteinuria in turn damages endothelium. In the same studies we found in 1969, but the relationship was not widely accepted until that estrogen, by enhancing glutathione levels, (GSH), 1976, when a controlled study showed a clear association leads to lower hydrogen peroxide concentrations and between moderately raised homocysteine and atherosalleviation of the endothelial injury. However, the enclerotic disease [32] . Since then, a possible association hancement of GSH by estrogen can not directly explain between homocysteine and atherothrombotic vascular diswhy homocysteine level decreases after estrogen adminisease has been examined in more than 12 000 patients tration. This phenomenon may be a fundamental effect of involving more than 100 cross-sectional, case-control, and estrogen / steroid action on cellular metabolism and the prospective studies (see for review Ref. [33] ). Crossbasis of many unclear pathological disturbances including sectional and retrospective case-control studies and one atherosclerosis. In the present review we will focus on large prospective observational study showed the strongest homocysteine biochemical metabolism and its interaction epidemiological evidence for a clear association between with estrogen's effects, particularly in vascular tissue.
hyperhomocysteinemia and vascular risk [33] [34] [35] [36] [37] . However, other prospective studies, including those examining the common thermolabile methyltetrahydrofolate reductase 2. Homocysteine (MTHFR) gene mutation associated with hyperhomocysteinemia, have not found a significant correlation High level of homocysteine is recognized as an inbetween hyperhomocysteinemia and cardiovascular disease dependent risk factor for atherosclerosis and cardiovascular [38, 39] . These inconsistent results may be due to the disease [15] . Hyperhomocysteinemia is associated with different methods used for serum homocysteine level myocardial infarction, coronary artery disease, strokes, measurements [40] and / or variability of homocysteine genetic disorders, Alzheimer's disease, and loss of cognilevels as a product of methionine transsulfuration / detive functions [16] [17] [18] [19] [20] [21] [22] [23] . Elevated plasma homocysteine methylation metabolism, depending on the individual diet levels are also associated with an increased risk of neuraland fasting state [41] . tube defect, placental infarcts, abruptio placenta, eclampsia, etc [24] [25] [26] [27] [28] , and some reports suggested that hyper-2.2. What do elevated levels of homocysteine actually homocysteinemia might be a manifestation of an underlymean? ing common biologic disorder which is directly associated with the process of DNA methylation [29, 30] .
A brief review of homocysteine metabolism associated Homocysteine is a key junctional metabolite in with metabolic disorders resulting in homocysteine acmethionine metabolism (Fig. 1) . It has two major metabolcumulation suggests several possible mechanisms for the ic fates: transmethylation catalyzed by methionine synthase observed effects. Either a genetic defect in one of the or betaine homocysteine methyl transferase and transsulfuenzymes of homocysteine metabolism or a nutritional ration catalyzed by cystathionine beta-synthase leading to deficiency of one or more of the vitamins that participate cystathionine (Fig. 1) . The latter is subsequently converted in homocysteine metabolism can lead to metabolic disrupto cysteine, a precursor of glutathione (GSH). Previous tion and potentially to hyperhomocysteinemia. In homostudies reveal that approximately half of the intracellular zygous cystathionine b-synthase (CbS) metabolic defect of patients with inborn methyltetrahydrofolate reductase are on ERT, compared to age-matched man and postdeficiency. Although the highest levels of homocysteine menopausal women who are not on ERT [58] [59] [60] [61] . These are observed in people with CbS deficiency, in those finding were officially recognized with a recently pubpatients the cardiovascular clinical events progress slowly lished statement of the Third National Health and Nutrition compared to the severe and rapid development of fatal Examination Survey that [62] : '' . . . higher estrogen status cardiovascular complications in patients with inborn defect is associated with a decreased mean serum total homoof methyltetrahydrofolate reductase, a disorder accomcysteine concentration, independently of nutritional status panied by only moderately elevated homocysteine conand muscle mass, and that estrogen may explain the centration [46] [47] [48] . Remarkably, severe dystrophic and previously reported male-female difference in total homoatrophic multiple organ changes found postmortem in cysteine concentration.'' patients with methyltetrahydrofolate reductase defect, Methyltetrahydrofolic acid is an essential methyl group pointing to depressed DNA-synthesis, are very similar to donor in homocysteine remethylation to methionine (Fig. those found in animals fed with methyl deficient diets.
1), and its essential element is folic acid. Folate deficiency Moreover, experiments in rats treated with 5-azacytidine correlates with development of severe atherosclerosis and (inhibitor of DNA methylation, used as a tool for DNA lower serum folate levels are associated with an increased demethylation) in different stages of development have risk of cerebrovascular and coronary artery disease [63] . shown the same results: severe impairment of the growth Folate deficiency also is the most common vitamin deand dystrophic and atrophic changes almost in all exficiency among pregnant women due to estrogen induced amined tissues [49] . In the context of these findings, increased turnover, suggesting that estrogen influences modified DNA methylation rather than hyperfolate utilization as well [64] . The comparatively low homocysteinemia itself may be the actual underlying levels of total homocysteine found in extra-embryonic pathology responsible for hyperhomocysteinemia-associcoelomic fluid and amniotic fluid, and the concomitant ated pathologic cell proliferation, degeneration and transhigh concentrations of methionine in these fluids is another formation.
finding suggesting that estrogen may interact with Hyperhomocysteinemia results in impaired balance bemethionine / homocysteine metabolism during early human tween methionine, SAM and S-adenosylhomocysteine development [65] . (SAH) [50, 51] . This imbalance may lead to changes in Hypothetically, the biochemical interaction between Smethyl-donor substrate levels and consequently to a modunitrosothiols and homocysteine may be a central mechanislation of DNA methylation pattern [30] . SAM availability tic feature in such diverse biological processes as infection, controls the binding capacity of DNA to methyltransferase neoplasia, neurologic disease, and atherosclerosis [66] [67] [68] [69] . and affects the velocity of methyltransferase reactions with
The vasodilatory, antiplatelet, antioxidant, antiproliferative, DNA and RNA [52] . The presence of SAM leads to and neuroregulatory actions of S-nitrosothiols oppose those improved recognition and stronger binding of the DNA attributed to homocysteine [70] . On the other hand, it is target by the methyltransferase, due to a conformational widely accepted that estrogen directly up-regulates nitric change of the enzyme to a more 'active' state [53] and oxide synthetase (NOS) activity and increases NO availa-2 SAM deficiency or its lower levels causes DNA hypo-and bility [71] [72] [73] [74] [75] . However, peroxynitrite (ONOO ) is a demethylation [54] . We and others have shown that highly cytotoxic molecule and could be produced in homocysteine causes atherosclerotic changes in vivo and conditions of high NO concentrations and superoxide significantly reduces endothelial cell viability in vitro availability (Fig. 2) . [13, 14, [55] [56] [57] . Although the concentrations utilized in our Estrogen dose-dependently increase myocardial and studies were significantly higher than those measured in plasma GSH levels [7, 13, 14] . The presence of GSH 2 the normal population, physiological concentrations of prevents ONOO formation by stabilizing the NO moleestrogen prevented homocysteine harmful effects and cule in GSNO (s-nitrosoglutathione), which is a redox form decreased its serum concentration in both controls and of NO, and produces specific cyto-protective effect [76] . hyperhomocysteinemic animals. Estrogen, by affecting GSNO also increases GSH formation by up-regulation of homocysteine / methionine metabolism, could impact on GSH synthesis and promotes hexose monophosphate shunt SAM levels and may relate to its action on DNA epi-(HPM shunt), thus reinforcing the GSH / GSSG system. genetic modifications.
Thus it seems that estrogen, by increasing GSH content, 2 limits the formation of ONOO and favors the production of GSNO [77] . Furthermore, estrogen by enhancing the 3. Estrogen and homocysteine activity of glucose-6 phosphate dehydrogenase (G6PDH) [13, 78] , the rate-limiting enzyme of the HMP shunt, Estrogen impact on methionine / homocysteine metaboincreases the capacity of NADPH, which acts as a colism may be a key aspect in elucidating its beneficial factor for NOS and replenishes GSH availability by effects. Lower levels of homocysteine are observed in donating hydrogen to its oxidative product GSSG. pregnant, premenopausal and postmenopausal women who
Together, this provides evidence supporting the theory which is a redox form of NO and deliver specific cyto-protective effects. Peroxynitrite (ONOO ) is a highly cytotoxic product from NO and superoxide. The presence of GSH prevents ONOO formation. GSNO increases GSH formation by up-regulation of GSH synthesis and promote HPM shunt, thus reinforcing GSH / GSSG system. (4) Estrogen increases glutathione peroxidase (GPX) activity, the enzyme catalyzed the scavenging of oxygen free radicals (FR) by GSH and its oxidation to GSSG. NADPH replenishes GSH availability by donating hydrogen to its oxidative product GSSG. (5) Estrogen could enhance cystathionine-b-synthase activity and directed homocysteine metabolism to forming cysteine and glutathione. (6) Estrogen probably influences on rate-limiting enzyme of glutathione synthesis.
that estrogen modulates thiol amino acid metabolism, 4. DNA methylation and estrogens particularly methionine metabolism. By interfering with the transsulfuration pathway, diminishing homocysteine Methylation of DNA is an important modification that and preventing its accumulation, estrogen may enhance the plays a global role in genome management and in the net production of GSH and stabilizes NO, which contriregulation of gene expression. This part of the review will butes to its beneficial effects on the vasculature.
briefly highlight the major findings in the methylation field over the past 20 years then summarize and juxtapose the unique process, in which a gene on one chromosome is most important and interesting relationships between essilenced, whereas its allele on the other chromosome is trogen effects and this modification of DNA. expressed), and the suppression of viral DNA sequences. The processes of methylation and demethylation of In eukaryotic organisms, DNA methylation is catalyzed by DNA are now generally accepted to have an epigenetic a SAM dependent DNA cytosine-5-methyltransferase, (alteration in gene expression without a change in nucleowhich catalyzes the transfer of a methyl group from SAM tide sequence) and a genetic control on cellular developto cytosine residues to form 5-methylcytosine, a modified ment, differentiation and transformation [79] . Mammalian base that is found at CpG islands (short sequences rich of development is accompanied by two major waves of the cytosine-guanine dinucleotide sites in the genome). genome-wide demethylation and remethylation, one during This catalysis involves nucleophilic attack by the thiol of germ-cell development and the other after fertilization the enzyme active site cysteine at the C6 position of [80] . Methionine is the general methyl donor in eukaryotic cytosine. In the absence of the cofactor-SAM this leads to cells and its concentrations directly influence methyl donor exchange of the C5 hydrogen (Fig. 4) , while the addition reactions with DNA, RNA, and other compounds [81] .
of SAM suppresses this exchange reaction and at its DNA methylation, or the covalent addition of a methyl saturating concentrations, cytosine receives a methyl group group to cytosine within the context of the CpG (cytosineand loses a proton from carbon 5, which stabilizes its guanine dinucleotide), has profound effects on the mamstructure. Methylation of cytosine within 59CpG islands is malian genome. These effects include transcriptional reassociated with loss of gene expression. Cytosine is the pression via inhibition of transcription factor (TF) binding most unstable base in DNA. Any mCpG sites are mutation (Fig. 3) or the recruitment of methyl-binding proteins and hot spots. About 100 cytosines are spontaneously deamitheir associated chromatin remodeling factors. Other efnated to thymidine (T). fects include X chromosome inactivation, imprinting (a Considerable effort has been invested in the elucidation Fig. 3 . DNA methylation. DNA methylation is a covalent addition of a methyl group to cytosine within the context of the CpG (cytosine-guanidine) dinucleotide and consequent transcriptional repression via inhibition of transcription factor (TF) binding In eukaryotic organisms DNA methylation is catalyzed by a SAM dependent DNA cytosine-5-methyltransferase, which catalyzes the transfer of a methyl group from SAM to cytosine residues to form 5-methylcytosine, a modified base that is found at CpG islands, short sequences rich of the cytosine-guanine dinucleotide sites in the genome. Methylation of cytosine within 59CpG islands is associated with loss of gene expression. Abbreviations: DMT, DNA methyltransferase; SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; MAT, methionine adenosyltransferase, TF, transcription factor; and CH , methyl group. Fig. 4 . Methylation of cytosine. Catalysis involves nucleophilic attack by the thiol of the enzyme active site cytosine at the C6 position of cytosine, which in the absence of the cofactor-SAM leads to exchange of the C5 hydrogen. The addition of SAM suppresses the exchange reaction and at its saturating concentrations cytosine receives methyl group and loses a proton from carbon 5, which stabilizes its structure.
of mechanisms that may contribute to the formation of regulating estrogenic effects on vasculature, reproductive methylated CpG sites and their demethylation in DNA.
tissues, bone, liver and brain. The longer term effects of Under a condition of limited availability of SAM, overall estrogen on atherosclerosis result from alterations in gene DNA hypomethylation and deamination of the target expression, and is believed to be mediated by ERs [112-cytosine to uracil, which codes from T during DNA 114] . Ligands, e.g. estradiol (E2), bind to the ligand replication, have been described [81, 82] .
binding domain (LBD) of ER and induce conformational Whether estrogen exerts its effects primarily via binding changes leading to high affinity ER homodimer binding to to the estrogen receptors (ER) has been subject of inestrogen response elements (ERE) on genes [83] . Many vestigation. ER is a member of the steroid / thyroid superobservations have supported the existence of different family of proteins that act as hormone-inducible transcripfunctional roles for estrogen receptor alpha (ER alpha) and tion factors. Two ER gene products, i.e. ER alpha and ER estrogen receptor beta (ER beta) in their cardioprotective beta, mediate the action of estrogens in target tissues, thus effects. ER alpha and beta are homogenous in some DNA binding domains, but other regions of the proteins share lar cells [92] . Functional ERs are present in the arterial little homology. The two receptors show significant differwall, endothelial cells, smooth muscle cells. The presence ence in their pattern of cell-specific expression, ligandof functional ERs is associated with protection against binding affinities and gene targets [112] . The precise coronary atherosclerosis [93, 94] . The level of circulating mechanism of transcriptional activation, or repression, by estrogens directly influences ER expression, and ERs the ER is unclear. The ER alpha promoter does not appear disappear shortly after menopause when the circulating to be methylated in situ (normal aorta), but becomes level of estrogen is low. Proliferation of vascular smooth methylated in proliferating aortic smooth muscle cells [86] . muscle cells is the most prominent hallmark of atheroAlteration in methylation associated with the smooth sclerosis, and a switching of the phenotype from contracmuscle cell phenotypic switch does not seem to require tile to de-differentiated phenotype is a key step in disease heightened activity of the methyltransferase enzyme, and progression. The process of change in cellular behavior appears to be selective for the ER alpha and a limited pool and phenotype during development of atherosclerosis is of genes whose CpG island becomes either demethylated very similar to that observed in carcinogenesis and esor de novo methylated. The genome of aortic smooth trogen has been shown to regulate cell proliferation in both muscle cells is responsive to environmental conditions, and cancer and vascular cells. Although alterations in DNA DNA methylation, in particular methylation of the ER methylation are well characterized in malignant tumors, alpha, could contribute to the switch in phenotype obthe presence of methylation changes in atherosclerosis has served in these cells. Surprisingly, it is reported that not been studied, even though excessive cellular proliferestrogen administration inhibits the vascular injury reation and alterations in gene expression characterize both sponse both in ovariectomized female ER alpha and ER diseases. In this context, the exact detection of the molecubeta knockout mice to the same extent as wild-type mice, lar mechanism(s) of estrogen action may lead to new bringing into question whether one of the ERs or another approaches in the treatment of coronary artery disease, and unidentified mechanism mediates the estrogen vascular a better understanding of the molecular mechanisms of protective effect [84, 85] . Could this be due to estrogen steroid action in carcinogenesis. induced modification of the epigenetic structure of DNA?
The first studies of estrogen mediated changes in DNA methylation pattern used genomic sequencing to examine 5. Estrogens, DNA methylation and development of the state of cytosine methylation in the upstream region of cancer? the avian vitellogenine gene [87] . Two methylated CpGs, present in the estrogen response element (ERE) become Although estrogens have many beneficial cardiovascular demethylated in liver and oviduct under the influence of actions, concerns have been raised about their effects on estradiol, suggesting the existence of estrogen dependent the progression of breast and uterine neoplasms, and DNA hypomethylation, which is not organ and / or tissue endometrial disease. The side effects of estradiol seem to specific. In another studies the total genomic DNA methbe associated with extensive hypo-and de-methylation of ylation in kidney tissues is decreased 11-24% in response DNA sequences responsible for the expression of some to estrogen treatment [88] . Demethylation of a CpG oncogenes ( Table 1) . Demethylation of these oncogenes located in the estrogen-response element (ERE) was activates their expression and is associated with condescribed in 1992 by Thakur and Kaur [89] . They observed sequent development of cancers in estrogen-sensitive that estrogen dose-dependently lowers the level of 5 tissues. On the other hand, the activation of other tumor methyl-cytosine (5mC) in uterus of young but showed no suppressor genes can lead to reduced amplification of effect in DNA methylation of uterus in old mice treated certain oncogenes. For example, the protective effect of with estradiol. Diethylstilbestrol (DES), a synthetic analog estrogen against chemically induced murine colon carcinoof estradiol, was recently found to produce an abnormal genesis is associated with CpG island demethylation and demethylation in the lactoferrin promoter [90] . Finally, increased mRNA and protein expression of the colonic Post et al. have proposed that the higher degree of vitamin D receptor [95] . Normal methylation pattern is methylation of ERs in a sub-population of cells of atherosfrequently disrupted in tumor cells with global hypoclerotic tissue compared to normal aortas causes lack of methylation accompanying region-specific hypermethyla-ER gene expression, resulting in an inability to respond to tion. When hypermethylation occurs within the promoter of estrogen's protective effects [91] . Based on such observaa tumor suppressor gene, this will silence the gene and tions, it could be hypothesized that methylated and inactiprovide the cell with a growth advantage in a manner akin vated ER gene in diseased vessels may prevent the to deletions or mutations. Tumor development and lower potential protective effects of estrogens in women with threshold for chemical carcinogenesis have been observed advanced atherosclerotic disease and therefore, account, at in experimental animals fed with a diet deficient in methyl least in part, for the lack of benefit observed in HERS group providing substances, leading to decreased availabilstudy.
ity of SAM. Low availability of SAM, high level of Estrogens can modulate directly the phenotype of vascuhomocysteine and reduced serum levels of folic acid (all these are cofactors in the remethylation pathway of homomeatless diet would help them against hypertension and cysteine to methionine) are all found in conditions of rapid heart disease (Hipocrates' teaching) Major religions cellular growth [96] .
prohibit eating of meat for certain periods of time in honor Higher or lower levels of estrogen are associated with of holidays (fasting). Interestingly, the only major source development or suppression of cancers in estrogen sensifor the essential amino acid methionine is the animal tive tissues and is related to the activation or inactivation proteins. Homocysteine is a product of the transsulfuration of certain genes by their hypo-or hypermethylation (see and demethylation of methionine and its high plasma Refs. in Table 1 ). This dual interaction between DNA levels are described to correlate with variety of diseases methylation status and estrogen level could provide new and especially atherosclerosis. Conversion of methionine molecular tools for better understanding and managing to homocysteine is associated with production of methyl estrogen-dependent diseases including atherosclerosis.
group that is donated to DNA, RNA, proteins, hormones, etc. Methylation of DNA is the major epigenetic modulator of gene expression associated with the early human 6. Concluding remarks development and is described as a molecular basis of carcinogenesis, atherosclerosis, aging, infection diseases, Disease phenotypes arise from complex interactions of genetic disorders and chromosomal imprinting. Estrogen organisms with their environment. While many specific has a long history as a potential beneficial drug against genes and gene defects have been associated with correcardiovascular disease, osteoporosis, Alzheimer disease, sponding disease phenotypes, a growing body of data etc. as a substance which can induce thrombo-embolic suggests that many disease phenotypes arise from the events and thrombotic disease, breast and uterine cancer. interactions of genes with their environments, including
Our review intended to provide a better understanding of the genetic background in which the genes are expressed. the molecular basis of estrogen effects and its possible Molecular mechanisms of some atherosclerosis-provoking interaction with methionine / homocysteine metabolism. factors seem to involve modifications of epigenetic switch, Reduction of the level of homocysteine by estrogen, either and some dietary factors also have the possibility to indirectly by its effect on gene expression, or directly by modify it. In the ancient times people believed that a effects on homocysteine synthesis, might account for the young women in relation to plasma total homocysteine, folate, and a specific estradiol-induced enhancement of endothelium common variant in the methylenetetrahydrofolate reductase gene.
resistance to harmful action of homocysteine and / or for its 
